The Latest Breaking News from Seagen

Pfizer stock careened lower Wednesday after the company issued disappointing 2024 guidance ahead of its acquisition of Seagen.

Pfizer announced Tuesday that it expects to complete this week its $43 billion acquisition of cancer-focused biotech company Seagen after clearing key regulatory hurdles.

Almost 68% of patients responded to an experimental bladder cancer treatment from Merck and Seagen. Merck stock jumped Monday.

Pfizer stock faces a steep patent cliff, but it's taken steps to offset the coming pressures. Will it be enough?

Shares of Pfizer and Citigroup are languishing near their 52-week lows. However, both stocks offer dividend yields in excess of 5%, and investors might want to buy these two undervalued income plays at current levels.

A bladder cancer treatment combo tied to a quartet of companies — including Seagen — succeeded in a study on Friday, leading SGEN stock to surge.

The Dow Jones rose Friday, bouncing after Thursday's market sell-off. Cathie Wood bought over 1 million shares of Palantir stock.

The markets have been on fire the past couple of weeks. While yesterday’s interest hike took some steam out of the markets, these three stocks and their options are unusually active and worthy of consideration.

Activision Blizzard shares rocketed after a court allowed Microsoft to proceed with its acquisition of the video game publisher.

US stock markets delivered stellar returns in the first half of the year and the Nasdaq 100 had its best first-half performance ever. However, Pfizer, whose COVID-19 vaccine made the company a household name recently fell to a 52-week low. Why is Pfizer stock going down and should you buy…

Big Pharma has a problem, and buying up biotech companies helps solve it. But the FTC has its own ideas about industry mergers. Here's where things stand.